Tempus AI, Inc. (TEM)
Automate Your Wheel Strategy on TEM
With Tiblio's Option Bot, you can configure your own wheel strategy including TEM - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol TEM
- Rev/Share 4.7114
- Book/Share 1.9131
- PB 30.6624
- Debt/Equity 2.6296
- CurrentRatio 1.7059
- ROIC -0.5453
- MktCap 9859129917.0
- FreeCF/Share -1.2473
- PFCF -46.3575
- PE -14.105
- Debt/Assets 0.5558
- DivYield 0
- ROE -5.3065
- Rating D+
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | TEM | BTIG Research | -- | Buy | -- | $60 | April 21, 2025 |
| Downgrade | TEM | JP Morgan | Overweight | Neutral | $50 | $55 | Feb. 25, 2025 |
| Downgrade | TEM | William Blair | Outperform | Market Perform | -- | -- | Feb. 12, 2025 |
| Resumed | TEM | TD Cowen | -- | Buy | $58 | $74 | Feb. 5, 2025 |
| Initiation | TEM | Wolfe Research | -- | Outperform | -- | $60 | Dec. 13, 2024 |
| Initiation | TEM | Guggenheim | -- | Buy | -- | $74 | Dec. 9, 2024 |
| Downgrade | TEM | BofA Securities | Buy | Neutral | $45 | $60 | Oct. 2, 2024 |
News
Tempus Fugit, Investors Regret? Short Seller Targets AI Darling, Warns CEO Is 'Cash Out King' (UPDATED)
Published: May 29, 2025 by: Benzinga
Sentiment: Negative
Editor's note: This story has been updated to include a statement from a Tempus AI spokesperson.
Read More
TEM Investor Notice: Levi & Korsinsky Investigates Tempus AI, Inc. for Securities Law Violations
Published: May 29, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 29, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Tempus AI, Inc. ("Tempus AI, Inc.") (NASDAQ:TEM) concerning possible violations of federal securities laws. Spruce Point Capital Management ("Spruce Point") published a report on Tempus, on May 28, 2025, describing a number of "concerns" about the Company.
Read More
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Tempus AI, Inc. (TEM) And Encourages Stockholders to Reach Out
Published: May 28, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / May 28, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Tempus AI, Inc. ("Tempus" or "the Company") (NASDAQ:TEM). Investors who purchased Tempus securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/TEM.
Read More
Tempus Fugit, Investors Regret? Short Seller Targets AI Darling, Warns CEO Is 'Cash Out King'
Published: May 28, 2025 by: Benzinga
Sentiment: Negative
Spruce Point Capital Management has announced a new short position against Tempus AI Inc. TEM. On Wednesday, the short seller raised concerns about the company's management team.
Read More
Tempus AI: Firing On All Cylinders
Published: May 25, 2025 by: Seeking Alpha
Sentiment: Positive
Tempus AI delivered strong Q1 results, driven by the Ambry Genetics acquisition and a major AstraZeneca contract, boosting revenue and backlog. The AI precision medicine company grew core revenues 32% YoY, but headline growth topped 75% due to the Ambry deal, though organic growth analysis is crucial for investors. The stock trades at a reasonable 7x '26 sales with 25-28% pro forma growth, but limited adjusted EBITDA targets may cap the valuation premium.
Read More
These Investors Search for ‘Extreme Winners.' Why Aurora, BYD, Tempus AI Make the Cut.
Published: May 23, 2025 by: Barrons
Sentiment: Positive
Lingotto Innovation's James Anderson and Morgan Samet favor companies with explosive growth potential and a focus on innovation.
Read More
Tempus AI: I Believe In The Company's Cause
Published: May 22, 2025 by: Seeking Alpha
Sentiment: Positive
I initiate coverage of Tempus AI, Inc. with a Buy rating, driven by its unique data assets and AI-powered oncology solutions. The company posted strong revenue growth and margin expansion, though profitability and high debt remain concerns as it integrates recent acquisitions. Tempus AI's vast clinical and molecular data, validated at major conferences, positions it as a key partner for leading pharma and healthcare companies.
Read More
Tempus to Present at the William Blair 45th Annual Growth Stock Conference
Published: May 21, 2025 by: Business Wire
Sentiment: Neutral
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, will participate in the William Blair 45th Annual Growth Stock Conference. The event will take place from June 3-5 in Chicago, IL. Jim Rogers, Chief Financial Officer of Tempus, will present on June 5. A live audio webcast of the presentation will be available here. About Tempus Tempus is a technology company advancing precision medicine throug.
Read More
Tempus: Is This Ultra-Fast-Growing Company A Good Investment?
Published: May 20, 2025 by: Seeking Alpha
Sentiment: Positive
Tempus AI, Inc. is growing rapidly in healthcare tech, especially genomics, but is not yet profitable and carries significant risk. Recent revenue growth is boosted by the Ambry Genetics acquisition; organic growth remains strong, but future growth may slow post-acquisition. The company benefits from exposure to large, expanding markets and leverages AI/data partnerships, but faces high valuation multiples.
Read More
These 3 AI-Related Stocks Crushed Earnings
Published: May 20, 2025 by: Zacks Investment Research
Sentiment: Positive
Earnings season continues to move rapidly, with many companies unveiling quarterly results daily. So far, the period has been positive, though it's worth noting that estimates for the current period (Q2) have trickled lower in recent weeks.
Read More
Big Earnings Beats: 6 Stocks That Spiked After Reporting Results
Published: May 13, 2025 by: 24/7 Wall Street
Sentiment: Neutral
We're winding down earnings season, and the old Wall Street adage that “earnings drive stock prices” continues to prove true.
Read More
These AI Stocks Posted Robust Results: Time to Buy?
Published: May 09, 2025 by: Zacks Investment Research
Sentiment: Positive
Several AI-related stocks have posted robust results throughout the Q1 earnings cycle, a list that includes Palantir and Tempus AI. Given their results, it's impossible to deny the staying power of AI, which is still likely in its early innings.
Read More
Tempus AI Stock: Time to Double Down or Cut and Run?
Published: May 08, 2025 by: MarketBeat
Sentiment: Positive
Tempus AI NASDAQ: TEM is an interesting AI story that operates a platform and library for diagnosis and drug discovery. The platform aids physicians by enabling personalized care for hard-to-treat illnesses and pharmaceutical companies like AstraZeneca NASDAQ: AZN, with advances in medicine impossible without computerized assistance.
Read More
Tempus AI, Inc. (TEM) Q1 2025 Earnings Call Transcript
Published: May 06, 2025 by: Seeking Alpha
Sentiment: Neutral
Tempus AI, Inc. (NASDAQ:TEM ) Q1 2025 Earnings Conference Call May 6, 2025 4:30 PM ET Company Participants Liz Krutoholow – Vice President-Investor Relations Eric Lefkofsky – Founder and Chief Executive Officer Jim Rogers – Chief Financial Officer Conference Call Participants Tejas Savant – Morgan Stanley Ryan MacDonald – Needham & Company Mark Schappel – Loop Capital Subbu Nambi – Guggenheim Daniel Brennan – TD Cowen Mark Massaro – BTIG Michael Ryskin – Bank of America Rachel Vatnsdal – JPMorgan Dan Arias – Stifel Operator Good day everyone. And thank you for standing by.
Read More
TEMPUS (Nasdaq: TEM) Earnings: Live Coverage And What to Expect
Published: May 06, 2025 by: 24/7 Wall Street
Sentiment: Neutral
Tempus AI (NASDAQ: TEM), a fast-rising player in clinical AI and health data infrastructure, will report its Q1 2025 earnings after the market closes today.
Read More
Tempus TIME Network Expands Support of Phase I Clinical Trials To Accelerate Activation and Enrollment
Published: May 01, 2025 by: Business Wire
Sentiment: Neutral
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, is leveraging its TIME Network to expand its support in phase I clinical trials. Since its inception in 2019, TIME has supported the rapid patient identification and site activation of clinical trials, bringing cutting-edge trials to patients in communities across the U.S. To further expand its support of phase I trials, Tempus has formed the T.
Read More
Tempus Publishes Study Validating the Benefits of xF+, its Comprehensive Liquid Biopsy Assay for Therapy Selection
Published: April 29, 2025 by: Business Wire
Sentiment: Neutral
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced publication of its study, “Analytical Validation of NGS-based Comprehensive Liquid Biopsy Assay for Therapy” in the Journal of Molecular Diagnostics. Data from this study supports the utility of xF+ as a non-invasive technique to detect actionable variants including resistance mutations, identify clinically relevant biomarkers,.
Read More
Discover Why Quantum Computing Stocks Are Soaring Today
Published: April 23, 2025 by: 24/7 Wall Street
Sentiment: Positive
With the stock market in rally mode, there are more pockets of strength than there have been in a while.
Read More
Tempus AI shares jump on new oncology AI partnerships with AstraZeneca, Pathos
Published: April 23, 2025 by: Proactive Investors
Sentiment: Positive
Tempus AI (NASDAQ:TEM) said on Wednesday it has signed multi-year strategic collaborations with AstraZeneca (AZN.L) and Pathos AI to co-develop what it called the largest multimodal foundation model in oncology, sending its shares up more than 15% in morning trading. The deals, which include $200 million in data licensing and model development fees to Tempus, will leverage the company's vast repository of de-identified oncology data and artificial intelligence capabilities to help identify new drug targets and advance cancer therapies.
Read More
Why Tempus AI Stock Is Skyrocketing Today
Published: April 23, 2025 by: The Motley Fool
Sentiment: Positive
Shares of Tempus AI (TEM 17.39%) were skyrocketing 16.5% higher as of 10:39 a.m. ET on Wednesday.
Read More
Why Quantum Computing (QUBT), Nano Nuclear Energy (NNE) and Tempus AI (TEM) Are Popping Higher Today
Published: April 22, 2025 by: 24/7 Wall Street
Sentiment: Positive
Analysts at BTIG initiated coverage of TEM with a buy rating with a price target of $60.
Read More
Tempus Unveils Advisory Board Featuring Leading Physicians From Across the U.S.
Published: April 18, 2025 by: Business Wire
Sentiment: Neutral
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the launch of the Tempus Advisory Board. The Tempus Advisory Board is a vital resource for the company in maintaining high standards and ensuring that the strategy and offerings continue to be grounded in expert knowledge from outside the organization. This group of engaged medical professionals is providing guidance, expertise.
Read More
Illumina and Tempus partner to drive the future of precision medicine through genomic AI innovation
Published: April 15, 2025 by: PRNewsWire
Sentiment: Neutral
Collaboration accelerates insights on clinical benefits of molecular profiling across all major categories of disease SAN DIEGO and CHICAGO , April 15, 2025 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN) and Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a collaboration to accelerate clinical adoption of next-generation sequencing tests through novel evidence generation. The collaboration will combine leading Illumina AI technologies with Tempus's comprehensive multimodal data platform to train genomic algorithms and ultimately accelerate clinical adoption of molecular testing for patients.
Read More
Tempus AI Surges 40% YTD: Are New Strategic Deals a Buy Signal?
Published: March 17, 2025 by: Zacks Investment Research
Sentiment: Positive
The market's appetite for AI applications in healthcare is rapidly increasing, with TEM emerging as a top contender in this high-growth sector.
Read More
Tempus Stock May Rise on the Acquisition of AI-Driven Deep 6 AI
Published: March 13, 2025 by: Zacks Investment Research
Sentiment: Neutral
TEM announces the acquisition of Deep 6 AI, enhancing its AI-driven clinical trial matching capabilities to accelerate patient recruitment and revolutionize precision medicine.
Read More
Should Investors Buy Tempus AI Stock Right Now?
Published: February 28, 2025 by: The Motley Fool
Sentiment: Neutral
Tempus AI (TEM -11.18%) is utilizing artificial intelligence to deliver better healthcare outcomes.
Read More
Tempus AI Falls 15% on Weak Q4 but EBITDA View Strong: Buy the Dip?
Published: February 26, 2025 by: Zacks Investment Research
Sentiment: Neutral
The acquisition of Ambry Genetics strengthens Tempus AI's genomics capabilities by adding a West Coast lab and expanding inherited risk testing.
Read More
Tempus AI Down 13%- Is It Time to Buy?
Published: February 25, 2025 by: 24/7 Wall Street
Sentiment: Negative
Shares of Nancy Pelosi's favorite artificial intelligence stock Tempus AI (NASDAQ:TEM) are falling more than 13% in morning trading after reporting fourth quarter and full-year 2024 earnings results yesterday after the market closed.
Read More
Tempus Stock Falls as Q4 Earnings & Revenues Miss Estimates
Published: February 25, 2025 by: Zacks Investment Research
Sentiment: Negative
TEM's fourth-quarter results reflect strong segmental performance. However, the company continues to incur losses at the operational level.
Read More
Tempus AI, Inc. (TEM) Q4 2024 Earnings Call Transcript
Published: February 24, 2025 by: Seeking Alpha
Sentiment: Neutral
Tempus AI, Inc. (NASDAQ:TEM ) Q4 2024 Earnings Conference Call February 24, 2025 4:30 PM ET Company Participants Liz Krutoholow - Investor Relations Eric Lefkofsky - Founder & Chief Executive Officer Jim Rogers - Chief Financial Officer Conference Call Participants Tejas Savant - Morgan Stanley Mike Ryskin - Bank of America Dan Brennan - TD Cowen Subbu Nambi - Guggenheim Doug Schenkel - Wolfe Research Andrew Brackmann - William Blair Mark Schappel - Loop Capital Dan Arias - Stifel David Westenberg - Piper Sandler Operator Thank you for standing by. My name is Jason, and I will be your conference …
Read More
About Tempus AI, Inc. (TEM)
- IPO Date 2012-03-28
- Website https://www.tempus.com
- Industry Medical - Diagnostics & Research
- CEO Mr. Eric P. Lefkofsky
- Employees 2400